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Non-competitive cyclic peptides for targeting enzyme-substrate complexes Table 4 for primer sequences)] at 95 °C for 5 min. After addition of Taq DNA polymerase to the eluate, the mixture was used for PCR amplification. The amplified DNA was purified by phenol/chloroform extraction followed by ethanol purification. The resultant DNA library was transcribed in vitro, ligated with the puromycin linker, and used for the next round of selection. For the 2nd-5th rounds of selection, small-scale (5 µL in 2nd, 2.5 µL in 3rd-5th) translation reactions were carried out. Reverse transcription of the mRNAs fused on peptides was buffer exchanged with selection buffer by gel-filteration. The resultant peptide library was subjected to biotin-bound dynabeads magnetic beads at 4 °C for 30 min, and then the supernatant was recovered (negative selection). After repeating the negative selection step 3 times, the recovered peptide solution was mixed with tPHD2-immobilized magnetic beads (4 pmol tPHD2 / µL loading), and incubated at 4 °C for 30 min. After the supernatant was removed, the beads were washed 3 times with 60 µL of cooled selection buffer. The collected cDNA-mRNA-peptide fusion was recovered with 100 µL of PCR buffer by incubation at 95 °C for 5 min and then amplified by Taq DNA polymerase. The amplified DNA was purified by phenol/chloroform extraction followed by ethanol purification. The resulting DNA library was transcribed in vitro, ligated with the puromycin linker, and used for the next round of selection. After the 5th round of the selection, the resulting cDNA library was cloned into the pGEM-T Easy Vector (Promega) and the individual clones were sequenced.
Illumina Sequencing
After sequencing, the variable region of each amplicon was extracted by removing the constant region and sequencing adaptors from reads using Cutadapt (version 1.8.1) 9 . The forward and reverse reads for each variable region were compared and non-identical reads were discarded in order to reduce downstream error due to sequencing errors. The resulting validated variable region sequences were tabulated using R and the resultant peptide determined using the Biostrings package 10 .
Chemical synthesis of selected macrocyclic peptides CP linear precursors were prepared with an amidated 'C-terminus' by standard solid phase synthesis on a CS Bio CS336X peptide synthesizer on Rink Amide MBHA resin using N,Nʹ-diisopropylcarbodiimide (DIC) as coupling reagent. After cleavage of the N-terminal Fmoc-protecting group a solution of 150 mg of chloroacetic acid succinimidyl ester in 4 mL DMF was added to the resin and the mixture shaken for 3 h. The resin was filtered off, washed and then subsequently treated with 4 mL of deprotection solution (95 % (v/v) CF3CO2H (TFA), 2.5 % (v/v) triisopropylsilane, 2.5 % (v/v) water). After 3 h the volume was reduced to 1 mL under a nitrogen stream and the peptides were precipitated with cold Et2O. The mixture was centrifuged and the supernatant discarded. The solid was taken up in 1.5 mL of triethylammoniumacetate buffer (1 M, pH 8.5) and the pH readjusted to > 8 if necessary. In a microwave (Biotage Initiator) the mixture was heated to 80 °C for 10 min and subsequently purified by HPLC (0-45 % MeCN in 45 min, 0.1 % TFA, Dionex Ultimate 3000 series, Grace Vydac 218TP101522 column). 8 Alternatively, peptides were prepared using a CEM Liberty Blue peptide synthesizer using Rink Amide MBHA resin with DIC as coupling reagent. After cleavage of the N-terminal Fmoc-protecting group, a solution of 150 mg chloroacetic anhydride in 5 mL dimethylformamide ((CH3)2NCH, DMF) was added and incubated for 40 min at room temperature. The resin was filtered, washed with DMF (3 × 10 mL) and dichloromethane (CH2Cl2, DCM) (3 × 10 mL), dried and cleaved from the resin with 5 mL of deprotection solution (92.5 % TFA, 2.5 % triisopropylsilane, 2.5 % water, 2.5% 1,3-dimethoxybenzene v/v) for 3 h. The cleaved peptide was precipitated with cold Et2O, dissolved in 10 mL of water/acetonitrile (1:1), and lyophilised. The dried linear peptides were dissolved in 6 mL of a 1:1 solution of acetonitrile/1M Triethylammonium acetate (pH 8.5), and transferred to microwave vials (0.5 -2 mL, glass vials). The contents were incubated at 80 °C for 10 minutes in a microwave synthesiser (Biotage Initiator) with stirring to induce cyclisation. The peptide solution was acidified using TFA, then purified by reverse-phase HPLC as described above. Peptide concentrations were determined using 1 H NMR and comparing the integrals of characteristic peaks in comparison with an internal standard of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid.
Strain promoted Azide-Alkyne cycloaddition
One equivalent of the azide-containing peptide (3CAz) was mixed with 1.5 eq of N-[(1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethyloxycarbonyl]-N′-biotinyl-1,8-diamino-3,6-dioxaoctane (biotin-BCN) in 1:1 H2O/MeCN and shaken at 37 °C for 5h. The desired product was obtained in high yield (>90%) and the purified by HPLC purification as above.
Biolayer interferometry
Experiments were performed using an OctetRed 384 (ForteBio) in BLI buffer (50 mM Tris-HCl (pH 7.5 at 22 °C), 200 mM NaCl, 0.05% (v/v) Tween-20 in some instances supplemented with 0.1% (w/v) BSA), at 25 °C. Protein was diluted into BLI buffer supplemented with 5-fold molar excess of ZnSO4 and 10-fold excess of 2-OG was loaded onto biosensors using a 1µM solution for Ni-NTA (Ninitrilotriacetic acid functionalised) biosensors and 50-100 nM for SA (streptavidin-functionalised) biosensors. The sensors were then subjected to a cycle of association/dissociation with different concentrations of peptides in BLI buffer + 1% DMSO. SA biosensors were additionally subjected to a 60 second blocking step with 1% (w/v) BSA in BLI buffer. Ni-NTA biosensors were regenerated as described in ForteBio Technical Note #31 and reused up to 10 times. Experiments with unfunctionalized SA biosensors to establish background binding to the sensors themselves showed negligible binding of peptides across the concentration ranges used. Higher peptide concentrations displaying complex binding curves and lower concentrations with insufficient signal magnitudes were excluded from fitting. Unless otherwise stated, all values are derived from fitting the kinetic data for the experiment -in some instances (for low affinity interactions) a steady-state approximation was used instead. Supplementary Cyclic peptides as substrates: Reaction components except enzyme were combined and incubated at 37 °C for 5 min before initiating the reaction by addition of enzyme from a stock of 5 × final concentration (also pre-incubated at 37 °C). Final concentrations of assay components were: tPHD2 (2 µM)*, 2-oxoglutarate (300 µM), Na-ascorbate (4 mM), (NH4)2Fe (SO4) 
NMR experiments
All spectra were acquired at 310 K. Cell culture and cell-based assays U2OS, Hep3B and RCC4 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma Aldrich D6546) supplemented with 10% fetal bovine serum (FBS)(Sigma Aldrich F7524), 2 mM Lglutamine (Sigma Aldrich G7513), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma Aldrich P0781). Cells were seeded to reach 60-70% confluency prior to compound and hypoxia treatment.
For investigation of the effect of CP treatments on PHD activity in cells, culture media was replaced with media pre-incubated in the targeted oxygen level hypoxia workstation overnight immediately after cells were moved into the hypoxic conditions. For testing CPs as inhibitors of HIF hydroxylases, the cells exposed to compounds at final 1% DMSO and in 20%, 5% or 1% oxygen level for designated times. Cells were harvested in urea/SDS buffer (6.7 M urea, 10 mM Tris-HCl pH 6.8, 10% glycerol, and1% SDS) supplemented with 1 mM dithiothreitol following a phosphate-buffered saline (PBS) rinse. Cell extracts were analyzed with SDS-PAGE and immunoblotted as described below.
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Capture assays
Cell pellets were lysed in lysis buffer (20 mM Tris pH 7.4 at 4 °C, 137 mM NaCl, 2 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton™ X-100) or cell extraction buffer (CEB; Thermo #FNN0011) with the addition of protease inhibitor cocktail (Sigma, #P8340) and 1 mM phenylmethylsulfonyl fluoride) for 30 min on ice with gentle mixing to resuspend every 10 min. The insoluble fraction was then precipitated by centrifugation (15 min, 13,000 × g) and the protein supernatant concentration determined by bicinchoninic acid BCA assay (Thermo #23227).
Western Blotting
Proteins were transferred at 320 mA for 25 min at room temperature with an ice-pack, in transfer buffer (10 mM Tris, 100 mM glycine, 10% (v/v) MeOH, 0.01% (w/v) SDS). The membrane was blocked using 5% (w/v) skimmed milk powder in PBST buffer (10 mM Na2HPO4, 1.8 mM K2HPO4 pH 7.4, 137 mM NaCl, 2.7 mM KCl, 0.1% (v/v) Tween-20) for 10 min and probed for 1 hr at room temperature or 4 °C overnight with primary antibodies. The membrane was washed PBST (3 × 10 min) before the membrane was incubated for 1 hr with HRP-conjugated secondary antibodies (Dako, #P0447). All antibody solutions contained 5% (w/v) skimmed milk powder in PBST buffer. The membrane was further washed with PBST (3 × 10 min) and bands visualised using super signal west dura ECL (Thermo #34075) and detected on a ChemiDoc™ (Bio-Rad #1708280).
Size-exclusion chromatography/multi-angle laser scattering
Samples were prepared with a tPHD2 concentration of 1 mg/mL, 36 µM in TBS (50 mM Tris pH 7.4 at 4 °C, 200 mM NaCl). To portions of this solution a series of 3C solutions in DMSO were added to give a final DMSO concentration of 1% v/v and final 3C concentrations of 0 µM, 11 µM, 22 µM and 44 µM. 100 µL of protein solution was injected onto a Superdex 200 HR 10/30 column (GE healthcare) pre-equilibrated with TBS and eluted species monitored using UV, multi-angle light scattering (Wyatt Dawn HELEOS-II 8-angle light scattering detector) and refractive index (Wyatt Optilab rEX refractive index monitor).
Non-denaturing ESI-MS Experiments
tPHD2 was desalted using a BioSpin 6 column (Bio-Rad, Hemel Hempstead, UK) into 15 mM ammonium acetate (pH 7.5). The stock of protein was then diluted with the same buffer to a final concentration of 100 µM. CODD peptide, 2OG, PHD2_004C and the inhibitor IOX3 (1-chloro-4-hydroxyisoquinoline-3-carbonyl)glycine 13 were also dissolved in 15 mM ammonium acetate (pH 7.5) to a final concentration of 100 µM. Combinations of these components were mixed and data were acquired as previously described 14 . (Fig 3) . PHD2 ± CODD from previous data. 
Supplementary Figures
Supplementary Figure 1. The PHD2 reaction. (A) PHD2 catalyzes hydroxylation of proline residues in HIF1-α using O2, 2OG, and a Fe(II). (B) O2 availability regulates activity of PHD2. In normoxia PHD2 hydroxylates HIF1-α which increases its affinity towards the von Hippel-Lindau protein, an E3 ubiquitin ligase, which marks HIF1-α for degradation by the proteasome. In hypoxia HIF1-α hydroxylation is reduced, leading to HIF1-α accumulation and translocation into the nucleus where it forms an active heterodimer with HIF1-β. This complex can bind to hypoxia response elements and increase transcription of HIF target genes, e.g.erythropoietin.
Supplementary Figure 2. Overview of the RaPID selection procedure.
The starting DNA template library (from 5'-to 3'-) consists of a T7 promoter, a GGG triplet, an epsilon sequence, a Shine-Dalgano sequence and a start codon (ATG), followed by 4-12 repeats of NNK codons encoding for all 20 proteinogenic amino acids, a cysteine codon, three glycine-serine repeats then a stop codon. 15 This library is transcribed into mRNA and ligated to a puromycin-derivatised oligonucleotide, and then used as the template for an in vitro translation reaction. This translation reaction mixture contains 19 proteinogenic amino acids (methionine omitted) and is supplemented with an initiator tRNA acylated with chloroacetyl D-tyrosine, allowing reprogramming of the start codon. After the translation step, the peptide is cyclised by an intramolecular reaction between the chloroacetyl group and a C-terminal cysteine. Crucially, the puromycin covalently links the coding mRNA strand to the corresponding translated CPs. Reverse transcription generates mRNA/cDNA-linked CPs and the mixture is incubated with magnetic beads to select for CPs that bind to the immobilized target. After series of washes, the cDNA associated with bound CPs are PCR amplified and sequenced. qPCR is used to measure the proportion of the input DNA recovered during each round. tPHD2HisBio selection recovery is shown (centre).
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